论文部分内容阅读
目的 探讨CD44蛋白在膀胱移行细胞癌中的表达及其临床意义。方法 应用免疫组织化学技术检测 55例膀胱移行细胞癌CD44蛋白的表达。结果 55例膀胱移行细胞癌中 ,CD44蛋白表达阳性率为 56 4% ,在膀胱移行细胞癌Ⅰ、Ⅱ、Ⅲ级中分别为 37 5%、60 %、68 4%。CD44表达分别与膀胱移行细胞癌病理分级和肿瘤大小无显著性差异 (P >0 0 5) ,与膀胱移行细胞癌转移有显著差异 (P <0 0 5)。结论 对CD44蛋白检测可以作为预测肿瘤转移的辅助指标
Objective To investigate the expression of CD44 protein in bladder transitional cell carcinoma and its clinical significance. Methods The expression of CD44 protein in 55 cases of bladder transitional cell carcinoma was detected by immunohistochemistry. Results The positive rate of CD44 protein was 56 4% in 55 cases of transitional cell carcinoma of the bladder and 37 5%, 60%, 68 4% in stage Ⅰ, Ⅱ and Ⅲ of bladder transitional cell carcinoma respectively. There was no significant difference between the expression of CD44 and the pathological grading and tumor size (P> 0.05) in transitional cell carcinoma of the bladder and the metastasis of bladder transitional cell carcinoma (P <0.05). Conclusion The detection of CD44 protein can be used as an auxiliary index in predicting tumor metastasis